URL: http://www.dailytarheel.com/index.php/article/2011/03/unc_center_to_lead_trials_for_colorectal_cancer_patients
Current Date: Thu, 24 May 2012 05:54:26 -0400
The Lineberger Comprehensive Cancer Center is slated to lead a clinical trial testing a new option for colorectal cancer patients whose illness has not subsided after first-line treatments.
About 40 percent of patients whose cancers contain certain mutant genes see their illnesses progress in spite of traditional primary treatments.
Dr. Richard Goldberg, associate director for clinical research at the Lineberger Cancer Center, is the trial’s principal investigator.
The study is sponsored financially by Bayer HealthCare AG, which will provide the medication free to patients involved in the trial.
It will begin this month and will involve 240 patients at the University and at other sites throughout North Carolina.
Do you think fracking can be done safely?
When it comes to colorectal cancer, an ounce of prevention is worth a pound of cure. While I guess that could be said of just about any disease, I think it’s more relevant for colorectal cancer because of the location (where most of the body’s waste is stored).
When it comes to colorectal cancer, an ounce of prevention is worth a pound of cure. While I guess that could be said of just about any disease, I think it’s more relevant for colorectal cancer because of the location (where most of the body’s waste is stored).
The Daily Tar Heel reserves the right to remove any comment deemed racially derogatory, inflammatory, or spammatory. Repeat offenders may have their IP address banned from posting future comments. Please be nice.
If this is the first time you've commented, your comment won't appear until you've verified your email address.
Flag this comment